Nrx announces completion of data safety meeting for phase 2 trial of brilife vaccine, phase 2b/3 registration trial to begin in nation of georgia, israel, european union, and other regions

Radnor, pa., dec. 06, 2021 (globe newswire) -- nrx pharmaceuticals (nasdaq:  nrxp ), today was advised that the independent data safety monitoring board overseeing the phase 2 trial of the brilife™ vaccine has concluded its safety analysis. a formal report is expected in the coming days. based on the input received, nrx is proceeding with its plans to initiate a phase 2b/3 registration trial of brilife (see www.clinicaltrials.gov nct04990466). nrx, working in concert with cromos, llc has received guidance in design of the trial from the european medicines agency and the world health organization.
NRXP Ratings Summary
NRXP Quant Ranking